Journal Overview

Welcome to the Jentashapir Journal of Cellular and Molecular Biology (JJCMB), published by Brieflands STM Publisher. JJCMB is dedicated to advancing knowledge in cellular and molecular biology through the publication of original research papers, reviews, meta-analyses, short communications, mini-reviews, case reports, and commentaries. The journal covers a wide range of topics, including basic, clinical, and translational studies, with a focus on new cellular and molecular techniques that enhance the prognosis, diagnosis, and early detection of human diseases and disorders. Since its rebranding in January 2020, JJCMB continues to showcase novel advancements and breakthroughs in the field of cellular and molecular biology.

Jentashapir Journal of Cellular and Molecular Biology
ISSN: e: 2717-2724
Frequency: quarterly

Abstracted/Indexed: Electronic Journal of Library | Scientific Information Database (SID) | Google Scholar | ISC | World Cat | Ricest | ROAD, more
Scope: All fields of Cellular and Molecular Biology, more
COPE member: Since 2017
Copyright Policy: CC BY-NC 4.0
Publishing Access: Open Access
Peer Review Policy: Double-Blind Peer Review System Open Peer Review

Recent Articles

3 articles
2025-03-31
vol. 16 , issue 1

Explore the latest articles published in this journal for impactful research and the newest advancements in the field.

24
Dec
2024
Jentashapir J Cell Mol Biol

From the Shadow of Virus Infection to Darkness of the Diabetes

Majid Komijani ORCID * , Amir Jalali ORCID , Gasan Hadi Diabil, Sarah Abulmahdi Zaghira, Mehdi Nodeh Farahani
|
Final Published
12
Jan
2025
Jentashapir J Cell Mol Biol

Comparison the Hippocampal Stathmin and TFEB Proteins Level in Animal Models of PTSD and Depression

Erfan Kavoosi ORCID , Solmaz Khalifeh ORCID , Mohammad Nasehi ORCID , Fatemeh Rohallah ORCID , Afshin Kheradmand ORCID , Farzaneh Nazari-Serenjeh ORCID *
|
Uncorrected Proof scheduled for 16 (1)
04
Jan
2025
Jentashapir J Cell Mol Biol

HL-10 Peptide as a Potential Therapeutic Agent for Cervical SiHa Cancer Cells

Zahra Setayesh-Mehr * , Leila Vafadar Ghasemi
|
Final Published

Journal Metrics

Discover our most recent insights and updates.
Submit to First Decision (Days):
17
Accept to Publication (Days):
17
Acceptance Rate (%) :
35.94
Article Processing Charges:
Free
Share it!

An official COPE member

Author Services

Brieflands Author Services

Contact Us!